Title: CARDS: The Collaborative Atorvastatin Diabetes Study
1CARDS The Collaborative Atorvastatin Diabetes
Study
-
- Purpose
- To assess the effectiveness of 10 mg
atorvastatin daily in the primary prevention of
cardiovascular disease in patients with type 2
diabetes, but without high concentrations of
LDL-cholesterol - Reference
- Colhoun HM, Betteridge PN, Hitman GA et al.
Primary prevention of cardiovascular disease with
atorvastatin in the Collaborative Atorvastatin
Diabetes Study (CARDS) multicentre randomised
placebo-controlled trial. Lancet
2004264685696.
2CARDS The Collaborative Atorvastatin Diabetes
Study - TRIAL DESIGN -
-
- Design
- Multicenter, multinational, randomized,
double-blind, parallel group - Patients
- 2838 patients aged 40-75 yrs with type 2
diabetes mellitus and at least one of
hypertension, retinopathy, albuminuria, smoking.
Patients with history of MI, angina, coronary
vascular surgery, cerebrovascular accident or
severe peripheral vascular disease ineligible -
- Follow up and primary endpoint
- Primary endpoint acute coronary event, coronary
revascularization, or stroke. Median 3.9 years
follow-up - Treatment
- Atorvastatin 10 mg per day or placebo
-
3CARDS The Collaborative Atorvastatin Diabetes
Study - TRIAL DESIGN continued-
Baseline characteristics
4CARDS The Collaborative Atorvastatin Diabetes
Study - RESULTS -
- Compared with placebo, patients receiving 10 mg
atorvastatin daily showed a 37 reduction in
major cardiovascular events from 9.0 to 5.8 (p
0.001) -
- There was a favourable trend in the atorvastatin
group with regard to all cause mortality, acute
coronary events, coronary revascularization, and
stroke - Adverse event rate similar in atorvastatin and
placebo groups. - No cases of rhabdomyolysis.
5CARDS The Collaborative Atorvastatin Diabetes
Study - RESULTS continued -
6CARDS The Collaborative Atorvastatin Diabetes
Study - RESULTS continued -
Breakdown of primary endpoint by treatment
7CARDS The Collaborative Atorvastatin Diabetes
Study - RESULTS continued -
8CARDS The Collaborative Atorvastatin Diabetes
Study - SUMMARY -
-
- Atorvastatin (10 mg, once daily) is safe and
effective in reducing the risk of cardiovascular
events, including stroke, in patients with type 2
diabetes - There was a favourable trend in the atorvastatin
group with regard to all cause mortality, major
coronary events, coronary revascularization, and
stroke